Savara Inc. Insider Trading

SVRA

Last 12 months

Insiders sold $2.36M and bought nothing on the open market.

None of the selling was scheduled in advance under a 10b5-1 plan. Chief Financial Officer David L Lowrance sold $2.24M on Jun 22, 42% of their stake, outside a plan. The last open-market buy by an executive or director was in Jun 2025.

Net open-market

−$2.36M

0 buys · 2 sales

Under a 10b5-1 plan

of the value sold

Insiders who bought / sold

0 / 2

executives and directors

Last open-market buy

Jun 2025

Jun 20, 2025

Get an email when SVRA's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

Date	Insider	Trade	Shares	Price	Value	Of their stake	Filing
Jun 22	David L Lowrance Chief Financial Officer	SoldNo plan	394,528	$5.68	$2.24M	42%	Form 4
Dec 19, 2025	David A Ramsay Director	SoldNo plan	20,000	$6.06	121K	0.8%	Form 4
Jun 20, 2025	Richard J Hawkins Director	Bought	48,225	$2.04	98K	72%	Form 4
May 29, 2025	Joseph S McCracken Director	Bought	10,000	$2.08	21K	4.0%	Form 4
Mar 31, 2025	David A Ramsay Director	Bought	150,000	$2.78	417K	6.3%	Form 4
Dec 16, 2024	David L Lowrance Chief Financial Officer	SoldNo plan	25,000	$3.33	83K	6.2%	Form 4
Dec 16, 2024	Matthew Pauls Chief Executive Officer	SoldNo plan	54,702	$3.31	181K	3.4%	Form 4
Dec 16, 2024	Richard J Hawkins Director	SoldNo plan	8,000	$3.32	27K	11%	Form 4
Nov 19, 2024	Joseph S McCracken Director	Bought	20,000	$2.95	59K	10%	Form 4
Nov 18, 2024	David A Ramsay Director	Bought	100,000	$2.88	288K	4.5%	Form 4

Jun 22No plan
David L Lowrance
Chief Financial Officer · sold 394,528 at $5.68
$2.24M
42% of stake
Dec 19, 2025No plan
David A Ramsay
Director · sold 20,000 at $6.06
121K
0.8% of stake
Jun 20, 2025
Richard J Hawkins
Director · bought 48,225 at $2.04
98K
72% of stake
May 29, 2025
Joseph S McCracken
Director · bought 10,000 at $2.08
21K
4.0% of stake
Mar 31, 2025
David A Ramsay
Director · bought 150,000 at $2.78
417K
6.3% of stake
Dec 16, 2024No plan
David L Lowrance
Chief Financial Officer · sold 25,000 at $3.33
83K
6.2% of stake
Dec 16, 2024No plan
Matthew Pauls
Chief Executive Officer · sold 54,702 at $3.31
181K
3.4% of stake
Dec 16, 2024No plan
Richard J Hawkins
Director · sold 8,000 at $3.32
27K
11% of stake
Nov 19, 2024
Joseph S McCracken
Director · bought 20,000 at $2.95
59K
10% of stake
Nov 18, 2024
David A Ramsay
Director · bought 100,000 at $2.88
288K
4.5% of stake

How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch SVRA, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Peers

Pharmaceutical Preparations · Pick stocks to compare with SVRA

CompareIntrinsic value

PRLDPrelude Therapeutics Incorporated

$4.08+7.94%40

PLRXPliant Therapeutics Inc.

$0.85-1.07%10

AARDAardvark Therapeutics, Inc.

$1.26+2.44%10

ORMPOramed Pharmaceuticals Inc.

$4.13+3.25%35

NTHINeonC Technologies Holdings

$3.17+3.26%10

SLNSilence Therapeutics plc

$19.80+0.10%10

SEPNSepterna, Inc.

$47.88+9.57%46

AXSMAxsome Therapeutics, Inc.

$137.00-1.87%10

Held by ETFs

SVRA is in 29 US ETFs. The largest of them, with SVRA's weight in each:

Spot a number that looks wrong? Check it in SVRA's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing SVRA

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.